Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis
Key result
Long-term celecoxib showed no significant benefit over diclofenac in avoiding severe gastrointestinal complications (RR 1.10; 95% CI 0.47-2.58).
Why the study?
Does celecoxib improve gastrointestinal safety compared to traditional NSAIDs in patients with osteoarthritis or rheumatoid arthritis?
Population
Patients with osteoarthritis or rheumatoid arthritis
Comparison
Celecoxib vs Traditional non-steroidal anti-inflammatory…
Design
Editorial
Follow-up
up to 15 months
Authors
Discussion
Loading...
Member takes
Overview
Long-term data show no celecoxib GI safety advantage over diclofenac; challenges prior reviews and leaves optimal NSAID choice open.
Structured PICO
Does celecoxib improve gastrointestinal safety compared to traditional NSAIDs in patients with osteoarthritis or rheumatoid arthritis?
P
Population
Patients with osteoarthritis or rheumatoid arthritis
I
Intervention
Celecoxib
C
Comparator
Traditional non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac
O
Outcome
Severe gastrointestinal complications (ulcer complications)safety
Main Result
Relative Risk: 1.1 (95% CI 0.47–2.58)
The authors challenge the findings of a previous systematic review, arguing that methodological flaws and short-term data misrepresent the long-term gastrointestinal safety of celecoxib compared to traditional NSAIDs.
Limitations
- Duplicate reports of trials were included as separate trials.
- Inappropriate pooling of trials with comparator drugs of different cyclo-oxygenase-2 selectivity.
- Differential patient withdrawal rates made study 035 results unreliable.
- Short-term results are misleading for chronic conditions.
Cite This Study
Peter Jüni (2003) conducted a letter in osteoarthritis and rheumatoid arthritis. Celecoxib vs. diclofenac was evaluated on severe gastrointestinal complications (RR 1.10, 95% CI 0.47-2.58). Long-term celecoxib showed no significant benefit over diclofenac in avoiding severe gastrointestinal complications (RR 1.10; 95% CI 0.47-2.58).